vancomycin has been researched along with Communicable Diseases in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (10.00) | 29.6817 |
| 2010's | 11 (55.00) | 24.3611 |
| 2020's | 7 (35.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lima, CSSDC; Lima, HAR; Silva, CSAGE | 1 |
| Abe, M; Inoue, E; Naito, Y; Okada, N; Okamoto, M; Sekido, M; Sugita, H; Tamatukuri, T; Tanaka, H; Tanaka, M; Yoshikawa, M | 1 |
| Bradley, JS; Le, J; Levine, DP; Liu, C; Lodise, TP; Lomaestro, B; Maples, HD; Mueller, BA; Pai, MP; Rodvold, KA; Rotschafer, JC; Rybak, MJ; Wong-Beringer, A | 1 |
| Girdwood, ST; Murphy, M; Scheetz, MH | 1 |
| Al-Nawaiseh, S; Becker, SL; Bisorca-Gassendorf, L; Boden, KT; Januschowski, K; Pérez Guerra, N; Seitz, B | 1 |
| Chae, JW; Goo, S; Jung, WJ; Kim, J; Park, JH; Shin, S; Yun, HY | 1 |
| Tabak, YP; Vankeepuram, L; Yamaga, C; Yu, KC | 1 |
| Chiyotanda, S; Kai, M; Kourogi, Y; Ogata, K; Setoguchi, N; Takamura, N; Tanaka, E; Tokunaga, J | 1 |
| Branch-Elliman, W; LaSalvia, MT; Schrank, GM; Wright, SB | 1 |
| Caraccio, J; Waters, CD | 1 |
| Al Zaibag, M; Aljohany, SM; Alothman, AF; Arabi, YM; Baharoon, S; Balkhy, HH; El-Metwally, A; El-Saed, A | 1 |
| Budin, G; Chung, HJ; Chung, J; Issadore, D; Lee, H; Weissleder, R | 1 |
| About, F; Berdougo, B; Brun-Buisson, C; De Pontfarcy, A; Delory, T; Emirian, A; Lesprit, P | 1 |
| Allegaert, K; Pfister, M; Samardzic, J; van den Anker, JN; Wilbaux, M | 1 |
| Gea-Banacloche, JC; Wade, JC | 1 |
| Bai, N; Cai, Y; Liang, B; Liu, Y; Wang, R | 1 |
| Babinchak, T; McGovern, P; Quintana, A | 1 |
| Morita, K | 1 |
| Colton, BJ; George, JM; Rodvold, KA | 1 |
| Simmons, JC | 1 |
5 review(s) available for vancomycin and Communicable Diseases
| Article | Year |
|---|---|
[Microbiological and infectious disease aspects of postoperative endophthalmitis].
Topics: Anti-Bacterial Agents; Communicable Diseases; Endophthalmitis; Eye Infections, Bacterial; Gram-Positive Bacteria; Humans; Retrospective Studies; Vancomycin | 2021 |
Quantitative clinical pharmacology practice for optimal use of antibiotics during the neonatal period.
Topics: Anti-Bacterial Agents; Bayes Theorem; Clinical Decision-Making; Communicable Diseases; Dose-Response Relationship, Drug; Drug Monitoring; Humans; Infant, Newborn; Kidney; Models, Biological; Neonatology; Vancomycin | 2016 |
Improvements in the prevention and management of infectious complications after hematopoietic stem cell transplantation.
Topics: Aspergillosis; Bacterial Infections; Communicable Diseases; Drug Resistance, Bacterial; Fever; Hematopoietic Stem Cell Transplantation; Humans; Immune System; Medical Oncology; Mycoses; Neutropenia; Pneumococcal Infections; Vancomycin | 2009 |
Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease.
Topics: Anti-Bacterial Agents; Communicable Diseases; Drug Resistance, Bacterial; Enterococcus; Humans; Methicillin-Resistant Staphylococcus aureus; Minocycline; Skin Diseases, Bacterial; Tigecycline; Vancomycin | 2011 |
[Optimization of antimicrobial therapy based on therapeutic drug monitoring].
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacteria; Communicable Diseases; Dose-Response Relationship, Drug; Drug Labeling; Drug Monitoring; Drug Resistance, Bacterial; Humans; Pharmacists; Pharmacokinetics; Professional Role; Vancomycin | 2011 |
15 other study(ies) available for vancomycin and Communicable Diseases
| Article | Year |
|---|---|
Late-onset neonatal infections and bacterial multidrug resistance.
Topics: Anti-Bacterial Agents; Bacterial Infections; Communicable Diseases; Cross-Sectional Studies; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Humans; Infant, Newborn; Microbial Sensitivity Tests; Oxacillin; Vancomycin | 2023 |
Evaluation of the initial timing of infection control pharmacist-driven audit and monitoring of vancomycin therapy in patients with infectious diseases: A retrospective observational study.
Topics: Aged; Communicable Diseases; Hospitals, University; Humans; Infection Control; Middle Aged; Pharmacists; Retrospective Studies; Vancomycin | 2023 |
Therapeutic Monitoring of Vancomycin for Serious Methicillin-resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatr
Topics: Anti-Bacterial Agents; Area Under Curve; Child; Communicable Diseases; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Pharmacists; Staphylococcal Infections; United States; Vancomycin | 2020 |
Clinical Guideline Highlights for the Hospitalist: Therapeutic Monitoring of Vancomycin.
Topics: Adult; Anti-Bacterial Agents; Child; Communicable Diseases; Hospitalists; Humans; Infant, Newborn; Methicillin-Resistant Staphylococcus aureus; Staphylococcal Infections; Vancomycin | 2020 |
Dose Optimization of Vancomycin Using a Mechanism-based Exposure-Response Model in Pediatric Infectious Disease Patients.
Topics: Anti-Bacterial Agents; Body Size; C-Reactive Protein; Child; Communicable Diseases; Dose-Response Relationship, Drug; Female; Humans; Male; Microbial Sensitivity Tests; Models, Biological; Vancomycin | 2021 |
Relationships between creatinine increase and mortality rates in patients given vancomycin in 76 hospitals: The increasing role of infectious disease pharmacists.
Topics: Adult; Communicable Diseases; Creatinine; Hospitals; Humans; Pharmacists; Retrospective Studies; Vancomycin | 2021 |
Establishment of a new initial dose plan for vancomycin using the generalized linear mixed model.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Communicable Diseases; Dose-Response Relationship, Drug; Female; Humans; Linear Models; Male; Models, Biological; Vancomycin | 2017 |
A retrospective analysis of adverse events among patients receiving daptomycin versus vancomycin during outpatient parenteral antimicrobial therapy.
Topics: Academic Medical Centers; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Communicable Diseases; Daptomycin; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Infusions, Parenteral; Logistic Models; Male; Middle Aged; Outpatients; Retrospective Studies; Vancomycin | 2018 |
Rate of positive cultures necessitating definitive treatment in patients receiving empiric vancomycin therapy.
Topics: Administration, Intravenous; Anti-Bacterial Agents; Bacterial Load; Colony Count, Microbial; Communicable Diseases; Hospitals; Humans; Methicillin-Resistant Staphylococcus aureus; Retrospective Studies; Staphylococcal Infections; Utah; Vancomycin | 2018 |
Antimicrobial consumption in five adult intensive care units: a 33-month surveillance study.
Topics: Adult; Anti-Bacterial Agents; Antimicrobial Stewardship; Carbapenems; Colistin; Communicable Diseases; Cost-Benefit Analysis; Drug Utilization; Female; Humans; Intensive Care Units; Male; Meropenem; Middle Aged; Piperacillin, Tazobactam Drug Combination; Population Surveillance; Saudi Arabia; Tertiary Care Centers; Vancomycin; Young Adult | 2018 |
μHall chip for sensitive detection of bacteria.
Topics: Anti-Bacterial Agents; Biosensing Techniques; Communicable Diseases; Cyclooctanes; Genotype; Gram-Positive Bacteria; Humans; Magnetite Nanoparticles; Microfluidic Analytical Techniques; Vancomycin | 2013 |
Impact of a program combining pre-authorization requirement and post-prescription review of carbapenems: an interrupted time-series analysis.
Topics: Aged; Carbapenems; Communicable Diseases; Drug Utilization; Drug Utilization Review; Female; Humans; Male; Middle Aged; Prescriptions; Prospective Studies; Tertiary Care Centers; Vancomycin | 2013 |
Clarification to the systematic review and meta-analysis involving tigecycline.
Topics: Anti-Bacterial Agents; Communicable Diseases; Humans; Minocycline; Vancomycin | 2011 |
National survey on continuous and extended infusions of antibiotics.
Topics: Anti-Bacterial Agents; beta-Lactams; Communicable Diseases; Drug Administration Schedule; Health Care Surveys; Humans; Infusions, Intravenous; Pharmacy Service, Hospital; Societies, Pharmaceutical; Time Factors; United States; Vancomycin | 2012 |
Infectious diseases pose new pressures but provide new opportunities for health care.
Topics: Communicable Disease Control; Communicable Diseases; Cross Infection; Drug Resistance, Microbial; Hospital Information Systems; Humans; Managed Care Programs; Sentinel Surveillance; Surgical Wound Infection; United States; Vancomycin | 2000 |